New Drug Approvals Archive - March 2011
Get news by email or subscribe to our news feeds.
See also: New Indications and Dosage Forms for March 2011
March 2011
Benlysta (belimumab) Injection
Date of Approval: March 10, 2011
Company: Human Genome Sciences, Inc. and GlaxoSmithKline
Treatment for: Systemic Lupus Erythematosus
Benlysta (belimumab) is B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of patients with systemic lupus erythematosus.
Gadavist (gadobutrol) Injection
Date of Approval: March 14, 2011
Company: Bayer HealthCare Pharmaceuticals Inc.
Treatment for: Diagnostic
Gadavist (gadobutrol) is a gadolinium-based contrast agent indicated for use in diagnostic magnetic resonance imaging (MRI).
(adenovirus type 4 and type 7 vaccine)
Date of Approval: March 16, 2011
Company: Barr Laboratories, Inc.
Treatment for: Infection Prophylaxis
Adenovirus type 4 and type 7 vaccine is an oral vaccine indicated for the prevention of febrile acute respiratory disease caused by adenovirus type 4 and type 7 in military populations.
Yervoy (ipilimumab) Injection
Date of Approval: March 25, 2011
Company: Bristol-Myers Squibb
Treatment for: Melanoma -- Metastatic, Renal Cell Carcinoma, Colorectal Cancer
Yervoy (ipilimumab) is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for the treatment of melanoma. Yervoy is also used in combination with Opdivo (nivolumab) for the treatment of advanced renal cell carcinoma, and microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer.
Sylatron (peginterferon alfa-2b)
Date of Approval: March 29, 2011
Company: Merck
Treatment for: Malignant Melanoma
Sylatron (peginterferon alfa-2b) is an alpha interferon indicated for the adjuvant treatment of melanoma.
New Drug Approvals Archive
2020January, February, March, April, May, June, July
2019January, February, March, April, May, June, July, August, September, October, November, December
2018January, February, March, April, May, June, July, August, September, October, November, December
2017January, February, March, April, May, June, July, August, September, October, November, December
2016January, February, March, April, May, June, July, August, September, October, November, December
2015January, February, March, April, May, June, July, August, September, October, November, December
2014January, February, March, April, May, June, July, August, September, October, November, December
2013January, February, March, April, May, June, July, August, September, October, November, December
2012January, February, March, April, May, June, July, August, September, October, November, December
2011January, February, March, April, May, June, July, August, October, November, December
2010January, February, March, April, May, June, July, August, September, October, November, December
2009January, February, March, April, May, June, July, August, September, October, November, December
2008January, February, March, April, May, June, July, August, September, October, November, December
2007January, February, March, April, May, June, July, August, September, October, November, December
2006January, February, March, April, May, June, July, August, September, October, November, December
2005January, February, March, April, May, June, July, August, September, October, November, December
2004January, February, March, April, May, June, July, August, September, October, November, December
2003January, February, March, April, May, June, July, August, September, October, November, December
2002January, February, April, May, July, August, October, November, December
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
